Cargando…

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide. A total of 70–80% of patients are diagnosed at an advanced stage with a dismal prognosis. Sorafenib had been the standard care for almost a decade until 2018 when the Food and Dru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longo, Vito, Brunetti, Oronzo, Gnoni, Antonio, Licchetta, Antonella, Delcuratolo, Sabina, Memeo, Riccardo, Solimando, Antonio Giovanni, Argentiero, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843273/ https://www.ncbi.nlm.nih.gov/pubmed/31627433 http://dx.doi.org/10.3390/medicina55100698

Ejemplares similares

Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
por: Gnoni, Antonio, et al.
Publicado: (2019)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Immune system and bone microenvironment: rationale for targeted cancer therapies
por: Gnoni, Antonio, et al.
Publicado: (2020)

Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
por: Argentiero, Antonella, et al.
Publicado: (2020)

Immunotherapeutic approaches for hepatocellular carcinoma
por: Longo, Vito, et al.
Publicado: (2017)

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
por: Leone, Patrizia, et al.
Publicado: (2021)

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era
por: Burgaletto, Chiara, et al.
Publicado: (2021)

Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside
por: Solimando, Antonio G., et al.
Publicado: (2020)

Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review
por: Argentiero, Antonella, et al.
Publicado: (2019)

Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
por: Argentiero, Antonella, et al.
Publicado: (2020)

Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions
por: Gnoni, Antonio, et al.
Publicado: (2013)

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
por: Makaremi, Shima, et al.
Publicado: (2021)

Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
por: Solimando, Antonio Giovanni, et al.
Publicado: (2021)

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview
por: Argentiero, Antonella, et al.
Publicado: (2019)

Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study
por: Argentiero, Antonella, et al.
Publicado: (2019)

A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery
por: Shadbad, Mahdi Abdoli, et al.
Publicado: (2021)

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
por: Longo, Vito, et al.
Publicado: (2019)

Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue
por: Longo, Vito, et al.
Publicado: (2016)

Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
por: Shahini, Endrit, et al.
Publicado: (2022)

Corrigendum: Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
por: Shahini, Endrit, et al.
Publicado: (2023)

MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
por: Brunetti, Oronzo, et al.
Publicado: (2015)

Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy
por: Fasano, Rossella, et al.
Publicado: (2021)

Actors on the Scene: Immune Cells in the Myeloma Niche
por: Leone, Patrizia, et al.
Publicado: (2020)

Angiogenesis in adenosquamous cancer of pancreas
por: Silvestris, Nicola, et al.
Publicado: (2017)

Gene Expression Comparison between Alcohol-Exposed versus Not Exposed Pancreatic Ductal Adenocarcinoma Patients Reveals a Peculiar TGFβ-Related Phenotype: An Exploratory Analysis
por: Doronzo, Antonio, et al.
Publicado: (2023)

Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm
por: Argentiero, Antonella, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Immune checkpoint inhibitor therapy for hepatocellular carcinoma
por: Ramai, Daryl, et al.
Publicado: (2022)

Visual Clustering of Transcriptomic Data from Primary and Metastatic Tumors—Dependencies and Novel Pitfalls
por: Marquardt, André, et al.
Publicado: (2022)

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow
por: Solimando, Antonio G., et al.
Publicado: (2022)

Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection
por: Paradiso, Angelo Virgilio, et al.
Publicado: (2020)

Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer
por: Lafranceschina, Stefano, et al.
Publicado: (2019)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond
por: Audisio, Alessandro, et al.
Publicado: (2022)

Varied functions of immune checkpoints during cancer metastasis
por: Safarzadeh, Ali, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
por: van Doorn, Diederick J., et al.
Publicado: (2020)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jekduqnu6aeumqbdn03jppc0ua